Viatris Finds A Buyer For India API Business, Other Assets, Ushering In New Era
Former Matrix Founder Set To Take Back Business Originally Sold 17 Years Ago
Viatris underlined a bold new vision early in 2022 when it announced the sale of its global biosimilars business to Biocon Biologics. Now it has moved to sell its remaining non-core units.
